Buprenorphine

Buprenorphine works on the same opioid receptors as heroin, fentanyl, and prescription painkillers, but it activates them only partially — enough to prevent withdrawal and reduce cravings, but not enough to produce a significant "high":

- Prevents withdrawal: By partially activating opioid receptors, buprenorphine prevents the painful withdrawal symptoms that drive relapse — nausea, muscle aches, anxiety, insomnia, and cravings. - Reduces cravings: The steady, moderate receptor activation reduces the intense cravings that people with OUD experience. - Blocks other opioids: Buprenorphine binds very tightly to opioid receptors. If someone takes heroin or fentanyl while on buprenorphine, the other opioid has difficulty attaching, greatly reducing its effects. - Safety ceiling: Unlike full opioid agonists (heroin, fentanyl), buprenorphine has a ceiling effect — increasing the dose beyond a certain point does not increase the opioid effect, which significantly reduces the risk of fatal overdose.

Why is naloxone included (Suboxone)? Naloxone is added to deter injection misuse. When taken sublingually as directed, naloxone is not absorbed and has no effect. But if the combination is dissolved and injected, naloxone blocks the opioid receptors and causes immediate withdrawal.

Induction (starting treatment): - Day 1: You must be in mild-to-moderate opioid withdrawal before taking the first dose (typically 12-24 hours after last short-acting opioid use, or 24-72 hours after long-acting opioids). The Clinical Opiate Withdrawal Scale (COWS) score should be ≥8-12. The first dose is typically 2-4 mg sublingual. - Day 1-3: Dose is increased in 2-4 mg increments every 1-2 hours (up to 8 mg on Day 1) until withdrawal symptoms are controlled. - Days 3-7: Target dose of 8-24 mg daily is reached. Withdrawal symptoms should be well controlled.

Stabilization (weeks 2-8): - Most patients stabilize at 12-16 mg/day. Cravings decrease significantly. Daily functioning improves.

Maintenance (months to years): - At stable doses, you should feel "normal" — not sedated, not in withdrawal. Many patients remain on buprenorphine for years. - Treatment retention rates at 12 months are significantly higher than placebo or behavioral treatment alone ^[3].

Food: Patients should not eat or drink for at least 15 minutes before and after sublingual administration to ensure proper absorption ^{[1, 2]}. The tablet or film is placed under the tongue and allowed to dissolve completely (5-10 minutes).

Alcohol: Alcohol combined with buprenorphine can cause dangerous respiratory depression — this is a BLACK BOX WARNING ^[1]. Patients should avoid alcohol entirely or minimize intake significantly.

Smoking: Smoking immediately before sublingual dosing may reduce oral pH and potentially affect absorption, though clinical significance is unclear.

Induction [1, 2, 3]: - Day 1: 2-4 mg SL; additional 2-4 mg after 1-2 hours if needed (max 8 mg Day 1) - Day 2: Total Day 1 dose + 4-8 mg if needed (max 16 mg) - Days 3-7: Titrate to suppress withdrawal; target 12-16 mg/day - Patient must be in mild-moderate withdrawal (COWS ≥8-12) before first dose

Maintenance [1, 2]: - Usual dose: 12-16 mg/day sublingual - Range: 4-24 mg/day (some patients require higher doses) - Maximum recommended: 24 mg/day

Sublocade (extended-release injection) [4]: - Must be stabilized on 8+ mg/day SL for at least 7 days before starting - 300 mg SQ monthly x 2 months, then 100 mg SQ monthly (may increase to 300 mg) - Administered by healthcare professional only (abdominal SQ injection)

Available formulations: - Sublingual film/tablets: 2 mg, 4 mg, 8 mg, 12 mg (with naloxone: 2/0.5, 4/1, 8/2, 12/3 mg) - Sublocade: 100 mg, 300 mg prefilled syringe

Costs vary significantly by formulation ^{[6, 7]}.

Pricing comparison: - Generic buprenorphine/naloxone sublingual film: $100-300/month - Brand Suboxone film: $300-600/month - Generic buprenorphine/naloxone tablets: $80-200/month - Sublocade injection: $1,500-1,800/injection

Cost-saving options: - Generic sublingual films and tablets provide substantial savings - Manufacturer assistance programs available for Suboxone and Sublocade - Medicaid covers buprenorphine in all 50 states - Many state programs provide MAT medications at no cost - The SAMHSA helpline (1-800-662-HELP) can help locate affordable treatment

Pregnancy: Buprenorphine is an accepted treatment for OUD during pregnancy and is recommended over medically supervised withdrawal, which is associated with high relapse rates ^{[1, 5]}.

- Buprenorphine monotherapy (Subutex — without naloxone) is preferred during pregnancy, though buprenorphine/naloxone (Suboxone) has also been used without clear evidence of harm ^[5] - The MOTHER trial showed buprenorphine-exposed neonates required less morphine treatment, had shorter hospital stays, and had shorter duration of NOWS compared to methadone-exposed neonates ^[5] - Neonatal opioid withdrawal syndrome (NOWS) is expected but treatable (black box warning) - Do NOT discontinue buprenorphine during pregnancy — relapse to illicit opioid use is far more dangerous

Breastfeeding: Buprenorphine is excreted in breast milk in small amounts. Breastfeeding is generally encouraged for mothers on stable buprenorphine doses who are not using illicit substances, as benefits of breastfeeding outweigh risks ^[5].

Generic buprenorphine/naloxone sublingual films and tablets are now available from multiple manufacturers, offering significant savings over brand Suboxone. The generics are FDA-rated as therapeutically equivalent. Some patients report taste or dissolution differences between brands, but clinical efficacy is equivalent. Sublocade (extended-release injection) has no generic equivalent.